Key result
Intravenous injection of SDF-1α-overexpressing bone marrow mesenchymal stem cells reduced inflammatory infiltration and systemic inflammatory factors, protecting heart function in mice.
Why the study?
To explore the potential therapeutic effect of SDF-1α-modified bone marrow mesenchymal stem cells on myocardial ischemia/reperfusion injury.
SDF-1α-overexpressing bone marrow mesenchymal stem cells demonstrate a potential protective effect against myocardial ischemia/reperfusion injury in a mouse model by reducing inflammation.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for SDF-1α-modified BMSCs in myocardial I/R; clinical translation remains untested.
A 2022 study studied Myocardial ischemia/reperfusion injury. Intravenous injection of SDF-1α-overexpressing bone marrow mesenchymal stem cells was evaluated on Myocardial injury and inflammatory infiltration. Intravenous injection of SDF-1α-overexpressing bone marrow mesenchymal stem cells reduced inflammatory infiltration and systemic inflammatory factors, protecting heart function in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: